Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Wajnberg, Ania, Amanat, Fatima, Firpo, Adolfo, Altman, Deena R., Bailey, Mark J., Mansour, Mayce, McMahon, Meagan, Meade, Philip +10 more·2020·Science
DOI 10.1126/science.abd7728

Cited by (1,007)

Items 301–400 of 1,007

  1. Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2
    Maya F. Amjadi, Sarah E. O’Connell, Tammy Armbrust, Aisha M. Mergaert, Sandeep Narpala, Peter Halfmann, S. Janna Bashar, Christopher R. Glover, Anna S. Heffron, Alison Taylor et al. · 2021 · ImmunoHorizons
  2. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity
    Sonia Tejedor Vaquero, Leire de Campos‐Mata, José María Ramada, Pilar Díaz, Juan Navarro‐Barriuso, Clara Ribas‐Llauradó, Natalia Rodrigo Melero, Carlo Carolis, Andrea Cerutti, Ramón Gimeno et al. · 2021 · Frontiers in Immunology
  3. Neutralizing Antibodies and Cellular Immune Responses Against SARS-CoV-2 Sustained One and a Half Years After Natural Infection
    Lina Yan, Panpan Liu, Xu-gui Li, Shi-jing Zhou, Hao Li, Zhi-yin Wang, Feng Shen, Bichao Lu, Yu Long, Xiao Xiao et al. · 2022 · Frontiers in Microbiology
  4. Pregnancy alters interleukin-1 beta expression and antiviral antibody responses during severe acute respiratory syndrome coronavirus 2 infection
    Morgan L. Sherer, Jun Lei, Patrick S. Creisher, Minyoung Jang, Ramya Reddy, Kristin Voegtline, Sarah Olson, Kirsten E. Littlefield, Han-Sol Park, Rebecca L. Ursin et al. · 2021 · American Journal of Obstetrics and Gynecology
  5. SARS‐CoV‐2 during pregnancy and associated outcomes: Results from an ongoing prospective cohort
    Nina M. Molenaar, Anna‐Sophie Rommel, Lot D. de Witte, Siobhan M. Dolan, Whitney Lieb, Erona Ibroçi, Sophie Ohrn, Jezelle Lynch, Christina Capuano, Daniel Stadlbauer et al. · 2021 · Paediatric and Perinatal Epidemiology
  6. An automated chemiluminescent immunoassay (CLIA) detects SARS-CoV-2 neutralizing antibody levels in COVID-19 patients and vaccinees
    Binjian Liu, Xibin Su, George Yu, Shu-Ling Yang, Feng Wang, Tao Huang, Liuyong Zhou, Zhiqiang Hui, Yixian Liao, Yuan Qiu et al. · 2021 · International Journal of Infectious Diseases
  7. Circular mRNA Vaccine against SARS-COV-2 Variants Enabled by Degradable Lipid Nanoparticles
    Ke Huang, Na Li, Yingwen Li, Jiafeng Zhu, Qianyi Fan, Jiali Yang, Yinjia Gao, Yuping Liu, Shufeng Gao, Peng Zhao et al. · 2025 · ACS Applied Materials & Interfaces
  8. SARS -CoV-2 T-cell immunity to variants of concern following vaccination
    Kathleen Gallagher, Mark B. Leick, Rebecca C. Larson, Trisha R. Berger, Katelin Katsis, Jennifer Y. Yam, Gabrielle Brini, Korneel Grauwet, MGH COVID-19 Collection & Processing Team, Marcela Valderrama Maus · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  9. SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod
    Lil Meyer‐Arndt, Julian Braun, Florent Fauchère, Kanika Vanshylla, Lucie Loyal, Larissa Henze, Beate Kruse, Manuela Dingeldey, Karsten Jürchott, Maike Mangold et al. · 2022 · Journal of Neurology Neurosurgery & Psychiatry
  10. The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic
    Linda Petrone, Alessandro Sette, Rory D. de Vries, Delia Goletti · 2023 · Pathogens
  11. Self-sampling of capillary blood for SARS-CoV-2 serology
    Lottie Brown, Rachel Louise Byrne, Alice J. Fraser, Sophie I. Owen, Ana I. Cubas-Atienzar, Christopher T. Williams, Grant A. Kay, Luís E. Cuevas, Joseph R A Fitchett, Tom E. Fletcher et al. · 2021 · Scientific Reports
  12. Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsort‐19 study
    Hubert Blain, Édouard Tuaillon, Lucie Gamon, Amandine Pisoni, Stéphanie Miot, Yves Rolland, Marie‐Christine Picot, Jean J. Bousquet · 2021 · Allergy
  13. kinetics of anti-SARS-CoV-2 antibodies over time. Results of 10 month follow up in over 300 seropositive Health Care Workers
    José Felipe Varona, Rodrigo Madurga, Francisco J. Peñalver, Elena Abarca, Cristina Almirall, Marta Cruz, Enrique Ramos, Jose María Castellano-Vazquez · 2021 · European Journal of Internal Medicine
  14. Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples
    Sasha E. Larsen, Bryan J. Berube, Tiffany Pecor, Evan Cross, Bryan P. Brown, Brittany D. Williams, Emma Johnson, Pingping Qu, Lauren P. Carter, Samuel P. Wrenn et al. · 2021 · Journal of Immunological Methods
  15. Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination
    Carlos A. Sariol, Petraleigh Pantoja, Crisanta Serrano-Collazo, Tiffany Rosa-Arocho, Albersy Armina-Rodríguez, Lorna A. Cruz, E. Taylor Stone, Teresa Arana, Consuelo Climent, Gerardo Latoni et al. · 2021 · Viruses
  16. Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition
    Agnieszka Katarzyna Macioła, Massimo La Raja, Monia Pacenti, Cristiano Salata, Giustina De Silvestro, Antonio Rosato, Giulia Pasqual · 2022 · Frontiers in Immunology
  17. Long-Term Persistence of Anti-SARS-COV-2 IgG Antibodies
    Zahra Yousefi, Niloofar Taheri, Motahareh Dargahi, Reza Chaman, Ehsan Binesh, Mohammad Hassan Emamian, Reza Jafari · 2022 · Current Microbiology
  18. Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort
    Dominik Menges, Kyra D. Zens, Tala Ballouz, Nicole Caduff, Daniel Llanas-Cornejo, Hélène Eloise Aschmann, Anja Domenghino, Céline Pellaton, Matthieu Perreau, Craig W. Fenwick et al. · 2022 · Nature Communications
  19. Innate and adaptive immunity to SARS-CoV-2 and predisposing factors
    Jiaying Shen, Junyan Fan, Yue Zhao, D. Jiang, Zheyun Niu, Zihan Zhang, Guangwen Cao · 2023 · Frontiers in Immunology
  20. Aptamers for Detection and Diagnostics (ADD): Can mobile systems process optical data from aptamer sensors to identify molecules indicating presence of SARS-CoV-2 virus? Should healthcare explore aptamers as drugs for prevention as well as its use as adjuvants with antibodies and vaccines?
    Shoumen Datta · 2020 · ChemRxiv
  21. Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study
    Jitao Wang, Qiran Zhang, Jingwen Ai, Dengxiang Liu, Chuan Liu, Huiling Xiang, Ye Gu, Ying Guo, Jiaojian Lv, Yifei Huang et al. · 2022 · Hepatology International
  22. Roles, Characteristics, and Analysis of Intrinsically Disordered Proteins: A Minireview
    Frederik Lermyte · 2020 · Life
  23. Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset
    Varun Sasisekharan, Niharika Pentakota, Akila Jayaraman, Kannan Tharakaraman, G. Wogan, Uma Narayanasami · 2021 · Proceedings of the National Academy of Sciences of the United States of America
  24. Impact of reproduction number on the multiwave spreading dynamics of COVID-19 with temporary immunity: A mathematical model
    B. Shayak, Mohit Sharma, Manas Gaur, Anand Kumar Mishra · 2021 · International Journal of Infectious Diseases
  25. COVID-19 reinfection in the presence of neutralizing antibodies
    Ju Zhang, Nan Ding, Lili Ren, Rui Song, Danying Chen, Xuesen Zhao, Budong Chen, Junyan Han, Jiarui Li, Yangzi Song et al. · 2021 · National Science Review
  26. Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses
    Houssein H. Ayoub, Hiam S. Chemaitelly, Monia Makhoul, Zaina Al Kanaani, Einas Al‐Kuwari, Adeel Ajwad Butt, Peter Valentine Coyle, Andrew M. Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif et al. · 2021 · BMJ Innovations
  27. Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration
    Sigrid Gouma, Madison E. Weirick, Marcus J. Bolton, Claudia P. Arevalo, Eileen C. Goodwin, Elizabeth M. Anderson, Christopher M. McAllister, Shannon R. Christensen, Debora Dunbar, Danielle Fiore et al. · 2021 · JCI Insight
  28. Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU
    Lorena Vigón, Javier García‐Pérez, Sara Rodríguez-Mora, Montserrat Torres, Elena Mateos, María Castillo de la Osa, Miguel Cervero, Rosa Malo de Molina, Cristina Navarro, María Aránzazu Murciano-Antón et al. · 2021 · Frontiers in Immunology
  29. High‐Affinity Dimeric Aptamers Enable the Rapid Electrochemical Detection of Wild‐Type and B.1.1.7 SARS‐CoV‐2 in Unprocessed Saliva
    Zijie Zhang, Richa Pandey, Jiuxing Li, Jimmy Gu, Dawn White, Hannah D. Stacey, Jann Catherine Ang, Catherine‐Jean Steinberg, Alfredo A. Capretta, Carlos D. M. Filipe et al. · 2021 · Angewandte Chemie
  30. Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York
    Luca Fierro, Nora Nesheiwat, Hetanshi Naik, Praveena Narayanan, Pramod Kumar Mistry, Manisha Balwani · 2020 · Molecular Genetics and Metabolism
  31. Biology of COVID-19 and related viruses: Epidemiology, signs, symptoms, diagnosis, and treatment
    Alan D. Kaye, Elyse M. Cornett, Kimberley C. Brondeel, Zachary I. Lerner, Haley E. Knight, Abigail P. Erwin, Karina Charipova, Kyle L. Gress, Ivan Urits, Richard D. Urman et al. · 2020 · Best practice & research. Clinical anaesthesiology
  32. What do we know about the antibody responses to SARS-CoV-2?
    Francisco Alejandro Lagunas‐Rangel, Venice Chávez‐Valencia · 2021 · Immunobiology
  33. Incidence, household transmission, and neutralizing antibody seroprevalence of Coronavirus Disease 2019 in Egypt: Results of a community-based cohort
    Mokhtar R. Gomaa, Amira S. El Refay, Mahmoud Shehata, Ahmed Kandeil, Mina Nabil Kamel, Mohamed A. Marouf, Mohamed GabAllah, Ahmed El Taweel, Ahmed E. Kayed, Omnia Kutkat et al. · 2021 · PLoS Pathogens
  34. Epidemiological Differences in the Impact of COVID-19 Vaccination in the United States and China
    Monia Makhoul, Hiam S. Chemaitelly, Houssein H. Ayoub, Shaheen Seedat, Laith Jamal Abu-Raddad · 2021 · Vaccines
  35. Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndrome Coronaviruses
    Joshua G. Petrie, Latifa A. Bazzi, Adrian B. McDermott, Dean A. Follmann, Dominic Esposito, Christian Hatcher, Allyson Mateja, Sandeep Narpala, Sarah E. O’Connell, Emily Toth Martin et al. · 2021 · The Journal of Infectious Diseases
  36. A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics
    Pinja Jalkanen, Arja H. Pasternack, Sari Maljanen, Krister Melén, Pekka Kolehmainen, Moona Huttunen, Rickard Lundberg, Lav Tripathi, Hira Khan, Mikael A. Ritvos et al. · 2021 · The Journal of Infectious Diseases
  37. Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis
    Eun-Jin Lee, Ji Eun Oh · 2021 · Molecules and Cells
  38. Vaccination of cancer patients against COVID-19: towards the end of a dilemma
    Avik Mandal, Pritanjali Singh, Arghadip Samaddar, Dharmendra Pratap Singh, Manika Verma, Amrita Rakesh, Rakesh Ranjan · 2021 · Medical Oncology
  39. Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection
    Luísa Canto e Castro, Andréia Gomes, Marta Serrano, Ana Helena Guia Pereira, Rita Ribeiro, Patrícia Napoleão, Inês Domingues, Cláudia Silva, Júlia Fanczal, Ângela Afonso et al. · 2021 · European Journal of Immunology
  40. A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens
    Shobha Upreti, Mukesh Samant · 2022 · Pharmaceutical Research
  41. The role and uses of antibodies in COVID-19 infections: a living review
    David Oliver Scourfield, Sophie G. Reed, Max N. Quastel, Jennifer Alderson, Valentina M T Bart, Alicia Teijeira Crespo, Ruth E. Jones, Ellie Pring, Felix Clemens Richter, David Ahern et al. · 2021 · Oxford Open Immunology
  42. The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19
    Daniele Focosi, Marco Tuccori, Massimo Franchini · 2021 · Life
  43. Seroprevalence of anti-SARS-CoV-2 IgG among healthcare workers of a large university hospital in Milan, Lombardy, Italy: a cross-sectional study
    Andrea Lombardi, Davide Mangioni, Dario Consonni, Lisa Cariani, Patrizia Bono, Anna Paola Cantù, Basilio Tiso, Michele Carugno, Antonio Muscatello, G. Lunghi et al. · 2021 · BMJ Open
  44. COVID-19 and Dentistry in 72 Questions: An Overview of the Literature
    Stéphane Derruau, Jérôme Bouchet, Ali Nassif, Alexandre Baudet, Kazutoyo Yasukawa, Sandrine Lorimier, Isabelle Prêcheur, Agnès Bloch‐Zupan, B. Pellat, Hélène Chardin et al. · 2021 · Journal of Clinical Medicine
  45. Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy
    Abhinay Gontu, Sreenidhi Srinivasan, Eric Salazar, Meera Surendran Nair, Ruth Helmus Nissly, Denver I. Greenawalt, Ian M. Bird, Catherine M. Herzog, Matthew Joseph Ferrari, Indira B. Poojary et al. · 2021 · Communications Biology
  46. Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults
    A. Wagner, A. Guzek, J. Ruff, J. Jasińska, U. Scheikl, I. Zwazl, M. Kundi, H. Stockinger, Maria R. Farcet, T. Kreil et al. · 2021 · Communications Medicine
  47. COVID-19 Research: Lessons from Non-Human Primate Models
    Laure Albrecht, Elodie Bishop, Basile Jay, Blaise Lafoux, Marie Minoves, Caroline Passaes · 2021 · Vaccines
  48. Neutralizing antibody: a savior in the Covid-19 disease
    Sneh Lata Gupta, Rishi Kumar Jaiswal · 2022 · Molecular Biology Reports
  49. Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
    Edwards Pradenas, Benjamin Trinité, Víctor Urrea, Sílvia Marfil, Ferran Tarrés-Freixas, Raquel Ortiz, Carla Rovirosa, Jordi Rodon, Júlia Vergara‐Alert, Joaquím Segalés et al. · 2022 · Cell Reports Medicine
  50. Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
    Jingjing Zhang, Han Zhang, Li-Tao Sun · 2022 · mAbs
  51. The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization
    Amy B. Karger, James D. Brien, Jayne M. Christen, Santosh Dhakal, Troy J. Kemp, Sabra L. Klein, Lígia A. Pinto, Lakshmanane Premkumar, John D. Roback, Raquel A. Binder et al. · 2022 · mSphere
  52. SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines
    Raju Sunagar, Amit Singh, Sudeep Kumar · 2023 · Vaccines
  53. COVID-19 Belgium: Extended SEIR-QD model with nursing homes and long-term scenarios-based forecasts
    Nicolas Franco · 2021 · Epidemics
  54. Dysregulated immunity in SARS-CoV-2 infected pregnant women
    Morgan L. Sherer, Jun Lei, Patrick S. Creisher, Minyoung Jang, Ramya Reddy, Kristin Voegtline, Sarah Olson, Kirsten E. Littlefield, Han-Sol Park, Rebecca L. Ursin et al. · 2020 · medRxiv
  55. Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines
    Ahmed Sayed Abdel-Moneim, Elsayed M. Abdelwhab, Ziad Ahmed Memish · 2021 · Virology
  56. Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases
    Tharmala Tharmalingam, Xiaobing Han, Ashley Wozniak, Laura L. Saward · 2021 · Human Vaccines & Immunotherapeutics
  57. IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers
    Rianna Vandergaast, Timothy S. Carey, Samantha Reiter, Chase Lathrum, Patrycja J. Lech, Clement W. Gnanadurai, Michelle Haselton, Jason Buehler, Riya Narjari, Luke Schnebeck et al. · 2021 · mSphere
  58. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern
    Marit J. van Gils, Hugo D.G. van Willigen, Elke Wynberg, Alvin X. Han, Karlijn van der Straten, Judith A. Burger, Meliawati Poniman, Melissa Oomen, Khadija Tejjani, Joey H. Bouhuijs et al. · 2021 · Cell Reports Medicine
  59. Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production
    Michael K. Müller, Johann Volzke, Behnam Subin, Silke C. Müller, Martina Sombetzki, Emil Christian Reisinger, Brigitte Müller‐Hilke · 2022 · BMC Medicine
  60. Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial
    Rolando Ochoa-Azze, Arturo Chang Monteagudo, Yanet Climent-Ruíz, Consuelo Macías Abraham, Carmen Valenzuela‐Silva, María de los Ángeles García-García, Yanet Jerez-Barceló, Yenisey Triana Marrero, Laura Ruiz-Villegas, Luis Dairon Rodríguez-Prieto et al. · 2022 · The Lancet Respiratory Medicine
  61. Sustained seropositivity up to 20.5 months after COVID-19
    Carlota Dobaño, Anna Ramírez‐Morros, Selena Alonso, Rocío Rubio, Gemma Ruiz‐Olalla, Josep Vidal‐Alaball, Dídac Macià, Queralt Miró Catalina, Marta Vidal, Aïna Fuster‐Casanovas et al. · 2022 · BMC Medicine
  62. Rapid biosensing SARS-CoV-2 antibodies in vaccinated healthy donors
    Sumin Bian, Min Shang, Mohamad Sawan · 2022 · Biosensors and Bioelectronics
  63. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study
    Shiwani Mahajan, Rajesh Srinivasan, Carrie A. Redlich, Sara K. Huston, Kelly M. Anastasio, Lisa Cashman, Daisy S. Massey, Andrew Dugan, Dan Witters, Jenny Marlar et al. · 2020 · The American Journal of Medicine
  64. Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency – Three consecutive cases and review of the literature
    Marcial Delgado‐Fernández, Gracia Mar García-Gemar, Ana Paula Fuentes, Manuel Isidro Muñoz-Pérez, Salvador Oyonarte, Ignacio Ruiz-García, Jesica Martín Carmona, Jaime Sanz‐Cánovas, Manuel Ángel Castaño-Carracedo, José María Reguera-Iglesias et al. · 2021 · Enfermedades Infecciosas y Microbiología Clínica
  65. AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 Emergency Use Authorization and Laboratory-Developed Test Serologic Testing in Clinical Laboratories
    Y Victoria Zhang, Joesph R Wiencek, Qing H. Meng, Elitza S. Theel, Nikolina Babić, Lusia Sepiashvili, Nicole Pecora, Patricia R. Slev, Andrew Cameron, Danijela Konforte · 2021 · Clinical Chemistry
  66. Immune profiling of COVID-19: preliminary findings and implications for the pandemic
    Holden Terry Maecker · 2021 · Journal for ImmunoTherapy of Cancer
  67. Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection
    Elisa Petruccioli, Saeid Najafi Fard, Assunta Navarra, Linda Petrone, Valentina Vanini, Gilda Cuzzi, Gina Gualano, Luca Pierelli, Antonio Bertoletti, Emanuele Nicastri et al. · 2021 · Journal of Translational Medicine
  68. Determinants and Dynamics of SARS-CoV-2 Infection in a Diverse Population: 6-Month Evaluation of a Prospective Cohort Study
    Daniel B. Horton, Emily S. Barrett, Jason Roy, Maria Laura Gennaro, Tracy Andrews, Patricia J. Greenberg, Natalie Bruiners, Pratik Datta, Rahul Ukey, Senthil Kumar Velusamy et al. · 2021 · The Journal of Infectious Diseases
  69. Modeling serological testing to inform relaxation of social distancing for COVID-19 control
    Alicia N.M. Kraay, Kristin Nelson, Conan Zhao, David Demory, Joshua S. Weitz, Benjamin Alan Lopman · 2021 · Nature Communications
  70. Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
    Moshe Shashar, Naomi Nacasch, Ayelet Grupper, Sydney Benchetrit, Tamar Halperin, Daniel Erez, Ilan Rozenberg, Pnina Shitrit, Yaron Sela, Ori Wand et al. · 2022 · American Journal of Nephrology
  71. Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark
    Kamille Fogh, Alexandra R. R. Eriksen, Rasmus Bo Hasselbalch, Emilie Sofie Kristensen, Henning Bundgaard, Susanne Dam Nielsen, Charlotte Sværke Jørgensen, Bibi F. S. S. Scharff, Christian Erikstrup, Susanne Gjørup Sækmose et al. · 2022 · BMC Infectious Diseases
  72. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong
    Zhou, Runhong, Liu, Na, Li, Xin, Peng, Qiaoli, Yiu, Cheuk-Kwan, Huang, Haode, Yang, Dawei, Du, Zhenglong, Kwok, Hau-Yee, Au, Ka-Kit et al. · 2023 · The Lancet Regional Health - Western Pacific
  73. Overview of Nucleocapsid-Targeting Vaccines against COVID-19
    Alexandra Ya. Rak, Исакова-Сивак Ирина Николаевна, Руденко Лариса Георгиевна · 2023 · Vaccines
  74. Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection
    K. M. Konrath, K. Liaw, Yuan-Han Wu, Xi-Zhou Zhu, Susanne N. Walker, Ziyang Xu, K. Schultheis, Neethu Chokkalingam, H. Chawla, Jianqiu Du et al. · 2022 · Cell Reports
  75. Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2
    Aleksei Titov, Regina Shaikhutdinova, Olga V. Shcherbakova, Yana V. Serdyuk, Savely A. Sheetikov, Ksenia V. Zornikova, Alexandra Vladimirovna Maleeva, Alexandra A. Khmelevskaya, Dmitry Vladimirovich Dianov, Naina T. Shakirova et al. · 2022 · JCI Insight
  76. The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera
    Steffen, Tara L., Stone, E. Taylor, Hassert, Mariah, Geerling, Elizabeth, Grimberg, Brian T., Espino, Ana M., Pantoja, Petraleigh, Climent, Consuelo, Hoft, Daniel F., George, Sarah L. et al. · 2020
  77. Kinetics and seroprevalence of SARS-CoV-2 antibodies in children
    Cathal Roarty, Claire L. Tonry, Lisa McFetridge, Hannah J Mitchell, Chris J Watson, Thomas Waterfield, Elizabeth Waxman, Derek Fairley, Gala Roew-Setz, James Patrick McKenna et al. · 2020 · The Lancet Infectious Diseases
  78. Systematic Examination of Antigen-Specific Recall T Cell Responses to SARS-CoV-2 versus Influenza Virus Reveals a Distinct Inflammatory Profile
    Jaclyn C. Law, Wan Hon Koh, Patrick Budylowski, Jonah Lin, F Yue, Kento T. Abe, Bhavisha Rathod, Mélanie Girard, Zhijie Li, James M. Rini et al. · 2020 · The Journal of Immunology
  79. Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG
    Kirsten Alexandra Eberhardt, Felix Dewald, Eva Heger, Lutz Gieselmann, Kanika Vanshylla, Maike Wirtz, Franziska Kleipass, Wibke Johannis, Philipp Schommers, Henning Gruell et al. · 2021 · Microorganisms
  80. Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients
    Shai Efrati, Merav Catalogna, Ramzia Abu Hamed, Amir Hadanny, Adina Bar‐Chaim, Patricia Benveniste‐Levkovitz, Refael Strugo, Osnat Levtzion‐Korach · 2021 · Scientific Reports
  81. SARS-CoV-2 Serologic Assays Dependent on Dual-Antigen Binding Demonstrate Diverging Kinetics Relative to Other Antibody Detection Methods
    Elitza S. Theel, Patrick W. Johnson, Katie L. Kunze, Liang Li Wu, Amy P. Gorsh, Dane Granger, Matthew M. Roforth, Calvin R. Jerde, Michael A. Lasho, Kylie J. Andersen et al. · 2021 · Journal of Clinical Microbiology
  82. Kinetics of anti-nucleocapsid IgG response in COVID-19 immunocompetent convalescent patients
    Mariam Movsisyan, Armine S. Chopikyan, Irina Kasparova, Gohar Hakobjanyan, Fabrice Carrat, Meline Sukiasyan, Marieta Rushanyan, Mariam Chalabyan, Sanobar Shariff, Burhan Kantawala et al. · 2022 · Scientific Reports
  83. After the virus has cleared—Can preclinical models be employed for Long COVID research?
    Ethan B. Jansen, S. N. Orvold, C. Swan, Anthony Yourkowski, Brittany Thivierge, Magen E. Francis, Anni Ge, Melissa L. Rioux, Joseph Darbellay, J. Howland et al. · 2022 · PLoS Pathogens
  84. Scientists have favorable opinions on immunity certificates but raise concerns regarding fairness and inequality
    Iván Aranzales, Ho Fai Chan, Reiner Eichenberger, Rainer Hegselmann, David Stadelmann, Benno Torgler · 2021 · Scientific Reports
  85. SARS-CoV-2-Specific and Functional Cytotoxic CD8 Cells in Primary Antibody Deficiency: Natural Infection and Response to Vaccine
    Sudhir Gupta, Sudhanshu Agrawal, Ashley Sandoval, Houfen Su, Michelle Tran, Yeşim Yılmaz Demirdağ · 2022 · Journal of Clinical Immunology
  86. Considerations for Novel COVID-19 Mucosal Vaccine Development
    Wael Alturaiki · 2022 · Vaccines
  87. Unraveling the role of the nucleocapsid protein in SARS-CoV-2 pathogenesis: From viral life cycle to vaccine development
    Yousra A. El‐Maradny, Moustafa A. Badawy, Kareem I. Mohamed, Renad F. Ragab, Hamssa M. Moharm, Nada A. Abdallah, Esraa M. Elgammal, Alberto Rubio‐Casillas, Vladimir Nikolaevich Uversky, Elrashdy M Moustafa Mohamed Redwan · 2024 · International Journal of Biological Macromolecules
  88. ‘Dark matter’, second waves and epidemiological modelling
    Karl John Friston, Anthony M de L Costello, Deenan Pillay · 2020 · BMJ Global Health
  89. Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Random Sample of Inhabitants of the Katowice Region, Poland
    Jan Eugeniusz Zejda, Grzegorz Marek Brożek, Małgorzata Kowalska, Kamil Barański, Angelina Patrycja Kaleta-Pilarska, Artur Nowakowski, Yuchen Xia, Paweł Eugeniusz Buszman · 2021 · International Journal of Environmental Research and Public Health
  90. Development and Validation of a Multiplex Microsphere Immunoassay Using Dried Blood Spots for SARS-CoV-2 Seroprevalence: Application in First Responders in Colorado, USA
    Jonathan S. Schultz, Mary K. McCarthy, Cody Rester, Katherine R. Sabourin, Kyle Annen, Melkon G. DomBourian, Elan Zohar Eisenmesser, Ashley A. Frazer‐Abel, Vijaya Knight, Thomas Jaenisch et al. · 2021 · Journal of Clinical Microbiology
  91. Automated ELISA On-Chip for the Detection of Anti-SARS-CoV-2 Antibodies
    Everardo Gonzalez‐González, Ricardo Garcia-Ramirez, Gladys Guadalupe Díaz-Armas, Miguel Esparza, Carlos Aguilar-Avelar, Elda A. Flores-Contreras, Iram Pablo Rodriguez-Sanchez, Jesús Rolando Delgado-Balderas, Brenda Soto‐García, Diana Araíz-Hernández et al. · 2021 · Sensors
  92. Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins
    Maryam Hojjat Jodaylami, Abdelhadi Djaïleb, Pierre Ricard, Étienne Lavallée, Stella Cellier-Goetghebeur, Megan-Faye Parker, Julien Coutu, Matthew Stuible, Christian Gervais, Yves Durocher et al. · 2021 · Scientific Reports
  93. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
    Lin Zhang, Josh Poorbaugh, Michael Lawrence Dougan, Peter Chen, Robert Gottlieb, Gregory D. Huhn, Stephanie Beasley, Montanea Daniels, Thi Ngoc Vy Trinh, Melissa Crisp et al. · 2021 · Frontiers in Immunology
  94. The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis
    Qi Chen, Kongxin Zhu, Xiaohui Liu, Chunlan Zhuang, Xingcheng Huang, Yue Huang, Xingmei Yao, Jiali Quan, Hongyan Lin, Shoujie Huang et al. · 2022 · Emerging Microbes & Infections
  95. Structure of a Vaccine-Induced, Germline-Encoded Human Antibody Defines a Neutralizing Epitope on the SARS-CoV-2 Spike N-Terminal Domain
    Clara G. Altomare, Daniel C. Adelsberg, Juan Manuel Carreño, Iden A. Sapse, Fatima Amanat, Ali H. Ellebedy, Viviana R. Simon, Florian Krammer, Goran Bajic · 2022 · mBio
  96. Genomic surveillance, evolution and global transmission of SARS-CoV-2 during 2019–2022
    Nadim Sharif, Khalid Jamaan Alzahrani, Shamsun Nahar Ahmed, Afsana Khan, Hamsa Jameel Banjer, Fuad M. Alzahrani, Anowar Khasru Parvez, Shuvra Kanti Dey · 2022 · PLoS ONE
  97. Clinical, Serological, Whole Genome Sequence Analyses to Confirm SARS-CoV-2 Reinfection in Patients From Mumbai, India
    Jayanthi S. Shastri, Swapneil Parikh, Sachee R Agrawal, Nirjhar Chatterjee, Manish Pathak, Sakshi Chaudhary, Chetan Sharma, Akshay Kanakan, Asokachandran Vivekanand, Janani Srinivasa Vasudevan et al. · 2021 · Frontiers in Medicine
  98. Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay
    Renee L Higgins, S. Rawlings, Jamie Case, F. Lee, C. Chan, Bethany L. Barrick, Z. Burger, K. Yeo, D. Marrinucci · 2021 · PLoS ONE
  99. Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2
    Llipsy Santiago, Iratxe Uranga-Murillo, Maykel A. Arias, Andrés Manuel González‐Ramírez, Javier Macías‐León, Eduardo Moreo, Sergio Redrado, Ana García‐García, Víctor Taleb, Erandi Lira‐Navarrete et al. · 2021 · Biology
  100. Diverse Humoral Immune Responses in Younger and Older Adult COVID-19 Patients
    Jennifer M. Sasson, Joseph J. Campo, Rebecca M. Carpenter, Mary K. Young, Arlo Z. Randall, Krista Trappl, Amit Oberai, Christopher Hung, Joshua M. Edgar, Andy Teng et al. · 2021 · mBio